Acetyl Hexapeptide-3

Identity and Sequence

Acetyl hexapeptide-3 is the original INCI name for the synthetic hexapeptide Ac-Glu-Glu-Met-Gln-Arg-Arg-NH₂ (Ac-EEMQRR-NH₂). Modern INCI filings usually list the same molecule as acetyl hexapeptide-8 — the renumbering reflects a cosmetic-naming convention change rather than any structural difference. The sequence is not taken from a hormone or a structural protein but from the N-terminal domain of SNAP-25, a 206-amino-acid protein of the SNARE complex that mediates vesicle docking and neurotransmitter release at nerve terminals. The peptide is, in effect, a mimic of a functional substructure of a synaptic protein.

Its commercial history is discussed separately under the brand name Argireline; the present page is focused on the biochemistry.

The SNARE Complex — What Acetyl Hexapeptide-3 Is Actually Imitating

Neurotransmitter release at the neuromuscular junction depends on the SNARE complex, a ternary assembly of three proteins: synaptobrevin (VAMP) on the vesicle membrane, and syntaxin-1 and SNAP-25 on the target plasma membrane. These three partners zipper together into a four-helix bundle that pulls the vesicle into close apposition with the plasma membrane, driving membrane fusion and the release of acetylcholine into the synaptic cleft. At the neuromuscular junction this release is what triggers muscle contraction — including the facial muscle contractions that etch dynamic expression wrinkles.

Acetyl hexapeptide-3 reproduces the first six residues of SNAP-25. The proposed mechanism is that the synthetic hexapeptide competes with intact SNAP-25 for assembly into the ternary SNARE complex; because the fragment cannot recruit the remainder of the bundle, the resulting complex is destabilized and fusion efficiency falls. Vesicle docking becomes less productive, acetylcholine release at any given stimulus is modestly reduced, and the sustained contraction intensity of underlying facial muscle tone is blunted.

How This Compares to Botulinum Toxin

Botulinum toxin type A — the active in Botox, Dysport, and Xeomin — also targets SNAP-25, but via a completely different biochemical strategy. Botulinum is a zinc-dependent endopeptidase that cleaves SNAP-25 between residues 197 and 198, destroying its ability to participate in SNARE assembly at all. The blockade is enzymatic, catalytic, long-lasting (3–4 months per injection), and localized by intramuscular delivery into specific target muscles.

Acetyl hexapeptide-3, by contrast, is a competitive stoichiometric inhibitor applied topically. It binds — or fails to productively bind — in proportion to its local concentration, exerts no catalytic destruction, and cannot meaningfully reach the motor end-plate because a 6-residue charged peptide crosses the stratum corneum only in minute quantities. The biochemistry is related; the pharmacology is not remotely comparable. Any product that implies otherwise is mis-stating the mechanism.

What the In Vitro Work Actually Shows

Cellular assays of acetyl hexapeptide-3 on PC12 cells and isolated SNARE complexes support the proposed competitive inhibition at micromolar-to-millimolar concentrations. Catecholamine release from stimulated chromaffin cells has been reported to fall by roughly 30% in these systems — a real effect, but at peptide concentrations orders of magnitude above what a topical serum can deliver across intact skin to viable nerve terminals. This concentration gap is the central honest limitation of the molecule.

Mechanistic Honesty

The clean molecular story — "SNAP-25 mimic that disrupts SNARE assembly" — is biochemically correct. The clinical translation story — "topical application of a hydrophilic hexapeptide to facial skin meaningfully reaches neuromuscular junctions at inhibitory concentrations" — is considerably harder to defend. Independent in vivo evidence that topically applied acetyl hexapeptide-3 produces SNARE inhibition in human facial skin at effective concentrations is thin. Most of the consumer-facing clinical evidence measures wrinkle geometry rather than any direct neuromuscular endpoint, which means the observed effect could plausibly be attributable to humectant and film-forming properties of the vehicle in addition to — or instead of — any true SNARE-level activity.

Regulatory and Research Status

Acetyl hexapeptide-3 is a cosmetic ingredient globally and has no drug approval or active investigational program. Its real-world safety record across two decades of retail use is excellent. For the commercial and consumer-facing perspective on the same molecule, see Argireline.